Neoadjuvant nivolumab improves survival in patients with resectable non-small cell lung cancer
1. Patients with resectable non-small cell lung cancer (NSCLC) receiving neoadjuvant nivolumab in addition to platinum-based chemotherapy demonstrated longer survival ...